Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)

NCT04937907 is registered in ClinicalTrials.gov with Shanghai Children's Hospital as lead sponsor.

NCT NCT04937907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04937907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
Lead sponsor
Shanghai Children's Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 8, 2021
Completion date
December 31, 2024
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome, x-linked